azd7648
Small moleculeexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 14, 2019 (NCT03907969)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- DNA-dependent protein kinaseINHIBITOR
PRKDC inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05116254 | Phase 1 | Mar 1, 2022 | Leiden University, Netherlands Cancer Institute, Radboud University |
| NCT03907969 | Phase 1/Phase 2 (Phase 2) | Oct 14, 2019 | AstraZeneca, Parexel, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 1 | 1 | 2019 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Netherlands Cancer Institute | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Parexel | For profit | 1 | 0 | 1 | 2019 |
| Radboud University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2019 |
6 organizations
Page 1 / 1